人肿瘤坏死因子样凋亡微弱诱导剂与系统性红斑狼疮的相关性研究
|
摘要
目的探讨人肿瘤坏死因子样凋亡微弱诱导剂(TWEAK)在系统性红斑狼疮(systemic lupus erythematosus,SLE)发病中的作用,通过检测外周血TWEAK的血清水平及mRNA表达水平,研究TWEAK的表达情况与系统性红斑狼疮患者临床与实验室特征的关联,从而为揭示TWEAK在SLE的发病中可能存在的作用提供依据。
方法选取安徽医科大学附属省立医院风湿免疫科的门诊及住院部系统性红斑狼疮患者组成病例组,随机抽取安徽医科大学第二附属医院健康体检中心的健康志愿者作为正常对照组。采用1997年美国风湿病学会修订的SLE分类标准作为诊断依据。在本课题中,共对33例SLE病人和15例健康对照进行了外周血白细胞中TWEAK mRNA的表达水平的检测,方法选用荧光定量聚合酶链反应(Fluorescent quantitative polymerase chain reaction, FQ-PCR)法;对62例SLE病人和15例正常对照的外周血清TWEAK浓度进行了检测,方法选用双抗体夹心酶联免疫吸附法(enzyme linked immunosorbent assay, ELISA)。调查获得研究对象知情同意后,抽取外周静脉血。收集患者一般情况和临床资料,同时进行SLE疾病活动指数(SLE disease activity index, SLEDAI)评分。实验所得数据用SPSS10.01进行统计分析,符合正态分布的两组间定量资料比较采用t检验;如不符合正态分布,采用Mann-Whitney秩和检验。资料符合双变量正态分布的两组间定量资料相关性分析,采用Pearson相关分析;如不符合正态分布,选取Spearman等级相关分析。检验水准α=0.05。
结果FQ-PCR结果显示SLE病人外周血单个核细胞中TWEAK的mRNA表达水平低于正常对照水平(P=0.001),活动组低于非活动组(P=0.025),然而狼疮肾炎组与狼疮非肾炎组差异无统计学意义(P=0.614)。ELISA结果表明SLE患者血清中TWEAK的浓度高于正常对照组(P<0.001)。另外,血管炎组高于非血管炎组(P=0.002),狼疮头痛组高于非狼疮头痛组(P=0.024),但是狼疮肾炎组与非肾炎组(P=0.989),活动组与非活动组(P=0.961)差异无统计学意义。
结论本研究发现病例组TWEAK的mRNA表达水平较对照组偏低,但血清TWEAK水平在SLE患者中升高,并且血管炎组高于非血管炎组,狼疮头痛组高于非狼疮头痛组,提示TWEAK可能与SLE发病相关。
Objective The aim of this study was to compare the mRNA and serum expression of Tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) in patients with systemic lupus erythematosus (SLE) and healthy controls.
Methods SLE patients were in- and out-patients of the Rheumatology Department in the Anhui Provincial Hospital. Age and sex-matched healthy controls were recruited at the second Affiliated Hospital, Anhui Medical University. Diagnosis of SLE was established according to the 1997 revised criteria of American College Rheumatology (ACR). Disease activity was evaluated using the SLE Disease Activity Index (SLEDAI) score. 62 patients and 15 healthy controls were recruited in the study. TWEAK messenger RNA (mRNA) expression in PBMC from 33 of 62 patients was detected by relative quantitation FQ-PCR. TWEAK concentrations in serum of all 62 patients were measured by Enzyme linked immunosorbent assay (ELISA).
The data were analyzed by the SPSS 10.01 software. Quantitative variables were described using mean±SD. Data in which variables demonstrated nonparametric distributions were expressed as median with interquartile range (IQR), and analyzed by Mann-Whitney U test for unpaired samples. Other data were analyzed with Student’s t test for unpaired values to compare differences between different control cultures. Pearson correlation or Spearman correlation were used to analyze the correlation between two continuous variables. A p value < 0.05 was considered statistically significant.
Results TWEAK mRNA expressions in PBMC were decreased in SLE patients compared with healthy controls (P=0.001). Lower TWEAK mRNA expression was also found in the active SLE patients when compared to inactive counterparties (P=0.025). However, there is no significant difference between LN patients and non-LN SLE patients (P=0.614). The serum level of TWEAK (sTWEAK) in SLE patients was increased when compared to healthy controls (P<0.001). In addition, the sTWEAK level was higher in SLE patients with vasculitis than that in SLE patients without vasculitis (P=0.002), the same was true in comparison between patients with and without headache (P=0.024). Nevertheless, no significant differences were found between active SLE patients and inactive patients (P=0.961), as well as between LN patients and non-LN SLE patients (P=0.989).
Conclusions In our study, SLE patients express reduced TWEAK mRNA but elevated level of sTWEAK, in addition, sTWEAK level was associated with several clinical manifestations of SLE, indicating that TWEAK may play a complex role in SLE.
方法选取安徽医科大学附属省立医院风湿免疫科的门诊及住院部系统性红斑狼疮患者组成病例组,随机抽取安徽医科大学第二附属医院健康体检中心的健康志愿者作为正常对照组。采用1997年美国风湿病学会修订的SLE分类标准作为诊断依据。在本课题中,共对33例SLE病人和15例健康对照进行了外周血白细胞中TWEAK mRNA的表达水平的检测,方法选用荧光定量聚合酶链反应(Fluorescent quantitative polymerase chain reaction, FQ-PCR)法;对62例SLE病人和15例正常对照的外周血清TWEAK浓度进行了检测,方法选用双抗体夹心酶联免疫吸附法(enzyme linked immunosorbent assay, ELISA)。调查获得研究对象知情同意后,抽取外周静脉血。收集患者一般情况和临床资料,同时进行SLE疾病活动指数(SLE disease activity index, SLEDAI)评分。实验所得数据用SPSS10.01进行统计分析,符合正态分布的两组间定量资料比较采用t检验;如不符合正态分布,采用Mann-Whitney秩和检验。资料符合双变量正态分布的两组间定量资料相关性分析,采用Pearson相关分析;如不符合正态分布,选取Spearman等级相关分析。检验水准α=0.05。
结果FQ-PCR结果显示SLE病人外周血单个核细胞中TWEAK的mRNA表达水平低于正常对照水平(P=0.001),活动组低于非活动组(P=0.025),然而狼疮肾炎组与狼疮非肾炎组差异无统计学意义(P=0.614)。ELISA结果表明SLE患者血清中TWEAK的浓度高于正常对照组(P<0.001)。另外,血管炎组高于非血管炎组(P=0.002),狼疮头痛组高于非狼疮头痛组(P=0.024),但是狼疮肾炎组与非肾炎组(P=0.989),活动组与非活动组(P=0.961)差异无统计学意义。
结论本研究发现病例组TWEAK的mRNA表达水平较对照组偏低,但血清TWEAK水平在SLE患者中升高,并且血管炎组高于非血管炎组,狼疮头痛组高于非狼疮头痛组,提示TWEAK可能与SLE发病相关。
Objective The aim of this study was to compare the mRNA and serum expression of Tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) in patients with systemic lupus erythematosus (SLE) and healthy controls.
Methods SLE patients were in- and out-patients of the Rheumatology Department in the Anhui Provincial Hospital. Age and sex-matched healthy controls were recruited at the second Affiliated Hospital, Anhui Medical University. Diagnosis of SLE was established according to the 1997 revised criteria of American College Rheumatology (ACR). Disease activity was evaluated using the SLE Disease Activity Index (SLEDAI) score. 62 patients and 15 healthy controls were recruited in the study. TWEAK messenger RNA (mRNA) expression in PBMC from 33 of 62 patients was detected by relative quantitation FQ-PCR. TWEAK concentrations in serum of all 62 patients were measured by Enzyme linked immunosorbent assay (ELISA).
The data were analyzed by the SPSS 10.01 software. Quantitative variables were described using mean±SD. Data in which variables demonstrated nonparametric distributions were expressed as median with interquartile range (IQR), and analyzed by Mann-Whitney U test for unpaired samples. Other data were analyzed with Student’s t test for unpaired values to compare differences between different control cultures. Pearson correlation or Spearman correlation were used to analyze the correlation between two continuous variables. A p value < 0.05 was considered statistically significant.
Results TWEAK mRNA expressions in PBMC were decreased in SLE patients compared with healthy controls (P=0.001). Lower TWEAK mRNA expression was also found in the active SLE patients when compared to inactive counterparties (P=0.025). However, there is no significant difference between LN patients and non-LN SLE patients (P=0.614). The serum level of TWEAK (sTWEAK) in SLE patients was increased when compared to healthy controls (P<0.001). In addition, the sTWEAK level was higher in SLE patients with vasculitis than that in SLE patients without vasculitis (P=0.002), the same was true in comparison between patients with and without headache (P=0.024). Nevertheless, no significant differences were found between active SLE patients and inactive patients (P=0.961), as well as between LN patients and non-LN SLE patients (P=0.989).
Conclusions In our study, SLE patients express reduced TWEAK mRNA but elevated level of sTWEAK, in addition, sTWEAK level was associated with several clinical manifestations of SLE, indicating that TWEAK may play a complex role in SLE.
引文
1.叶冬青.红斑狼疮.北京:人民卫生出版社, 2006
2.曹秀菁,叶冬青,李向培,等.女性系统性红斑狼疮患者血清性激素变化.中华疾病控制杂志, 2004;8:415-7
3. Foster D, Parrish-Novak J, Fox B, et al. Cytokine-receptor pairing: accelerating discovery of cytokine function. Nat Rev Drug Discov 2004; 3:160–70.
4.袁慧,叶冬青. JAK/STAT信号通路与系统性红斑狼疮.中华疾病控制杂志, 2010;14:787-90.
5.陶金辉,李向培,厉小梅,等. IFNγ在系统性红斑狼疮发病中的作用和临床意义.中华疾病控制杂志,2005; 9:278-80.
6. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008; 7:411–25.
7. Nakayama M, Kayagaki N, Yamaguchi N, et al. Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity. J Exp Med 2000; 192:1373- 80.
8. Perper SJ, Browning B, Burkly LC, et al. TWEAK is a novel arthritogenic mediator. J Immunol 2006; 177:2610-20.
9. Kaplan MJ, Lewis EE, Shelden EA, et al. The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells. J Immunol 2002; 169:6020-9.
10. Desplat-Jégo S, Feuillet L, Creidy R, et al. TWEAK is expressed at the cell surface of monocytes during multiple sclerosis. J Leukoc Biol 2009; 85:132-5.
11. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI: a disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum 1992; 35: 630-40.
12.夏江莉,李向培,钱龙,等.系统性红斑狼疮患者血清HMGB1水平检测及临床意义.临床输血与检验, 2009; 11: 242-3.
13. Chicheportiche Y, Bourdon PR, Xu H, et al. TWEAK, a new secreted ligand in the tumor necrosis factor familiy that weakly induces apoptosis. J Biol Chem 1997; 272: 32401-10.
14. Wiley SR, Cassiano L, Lofton T, et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 2001; 15: 837-46.
15. Meighan-Mantha RL, Hsu DK, Guo Y, et al. The mitogen-inducibleFn14 gene encodes a type I transmembrane proteinthat modulates fibroblast adhesion and migration. J Biol Chem 1999; 274: 33166-76.
16. Winkles J A, Tran N L, Brown S A, et al. Role of TWEAK and Fn14 in tumor biology. Front Biosci 2007; 12: 2761-71.
17. Ortiz A, Sanz AB, Mun?oz Garc?′a B, et al. Considering TWEAK as a target for therapy in renal and vascular injury. Cytokine Growth Factor Rev 2009; 20:251-8.
18. Yepes M. TWEAK and the central nervous system. Mol Neurobiol 2007; 35:255- 65.
19. Yepes M. TWEAK and FN14 in central nervous system health and disease. Front Biosci 2007; 12:2772-81.
20. Zhao Z, Burkly LC, Campbell S, et al. TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. J Immunol 2007; 179:7949-58.
21. Schwartz N, Su L, Burkly LC, et al. Urinary TWEAK and the activity of lupus nephritis. J Autoimmun 2006; 27:242-50.
22. Manoharan A, Madaio MP. Biomarkers in lupus nephritis. Rheum Dis Clin North Am 2010; 36:131-43.
23. Chicheportiche Y, Fossati-Jimack L, Moll S, et al. Down-regulated expression of TWEAK mRNA in acute and chronic inflammatory pathologies. Biochem Biophys Res Commun 2000; 279:162-5.
24. Zheng TS, Burkly LC. No end in site: TWEAK/Fn14 activation and autoimmunity associated- end-organ pathologies. J Leukoc Biol 2008; 84:338-47.
25. Leng RX, Pan HF, Qin WZ, et al. TWEAK as a target for therapy in systemic lupus erythematosus. Mol Biol Rep 2011; 38:587-92.
26. ElGendi SS, El-Sherif WT. Anti-C1q antibodies, sCD40L, TWEAK and CD4/CD8 ratio in systemic lupus erythematosus and their relations to disease activity and renal involvement. Egypt J Immunol 2009; 16:135-48.
27. Schwartz N, Rubinstein T, Burkly LC, et al. Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther 2009; 28:R143
1.叶冬青(主编).红斑狼疮.北京:人民卫生出版社, 2006.
2. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008; 7:411-25.
3. Nakayama M, Kayagaki N, Yamaguchi N, et al. Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity. J Exp Med 2000; 192:1373-80.
4. Desplat-Jégo S, Feuillet L, Creidy R, et al. TWEAK is expressed at the cell surface of monocytes during multiple sclerosis. J Leukoc Biol 2009; 85:132-5.
5. Kaplan MJ, Lewis EE, Shelden EA, et al. The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells. J Immunol 2002; 169:6020-9.
6. Chicheportiche Y, Bourdon PR, Xu H, et al. TWEAK, a new secreted ligand in the tumor necrosis factor familiy that weakly induces apoptosis. J Biol Chem 1997; 272: 32 401-10.
7. Lynch CN, Wang YC, Lund J K, et al. TWEA K induces angiogenesis and proliferation of endothelial cells. J Biol Chem 1999; 274: 8455-59.
8. Wiley SR, Cassiano L, Lofton T, et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 2001; 15: 837-46.
9. Meighan-Mantha RL, Hsu DK, Guo Y, et al. The mitogen-inducibleFn14 gene encodes a type I transmembrane proteinthat modulates fibroblast adhesion and migration. J Biol Chem 1999; 274: 33166-76
10. Feng SL, Guo Y, Factor VM, et al. The Fn14 immediateearly response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am J Pathol 2000; 156:1253-61
11. Jakubowski, A. et al. TWEAK induces liver progenitor cell proliferation. J ClinInvest 2005; 115:2330-40
12. Vince JE, Chau D, Callus B, et al. TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha. J Cell Biol 2008; 182:171-84.
13. Dai L, Gu L, Ding C, Qiu L, et al. TWEAK promotes ovarian cancer cell metastasis via NF-kappaB pathway activation and VEGF expression. Cancer Lett 2009; 283:159-67
14. Hosokawa Y, Hosokawa I, Ozaki K,et al. Proinflammatory effects of tumour necrosis factor-like weak inducer of apoptosis (TWEAK) on human gingival fibroblasts. Clin Exp Immunol 2006; 146:540-9.
15. Brown SA, Richards CM, Hanscom HN, et al. The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-kappaB activation. Biochem J 2003; 371:395-403.
16. Donohue PJ, Richards CM, Brown SA, et al. TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler Thromb Vasc Biol 2003; 23:594-600.
17. Winkles J A, Tran N L, Brown S A, et al. Role of TWEAK and Fn14 in tumor biology. Front Biosci 2007; 12: 2761-71.
18. Kumar M, Makonchuk DY, Li H, et al. TNF-like weak inducer of apoptosis (TWEAK) activates proinflammatory signaling pathways and gene expression through the activation of TGF-beta-activated kinase 1. J Immunol 2009; 182: 2439-48.
19. Nakayama M, Ishidoh K, Kayagaki N, et al. Multiple pathways of TWEAK-induced cell death. . J Immunol 2002; 168:734-43
20. Ebihara N, Nakayama M, Tokura T, et al. Expression and function of fibroblast growth factor-inducible 14 in human corneal myofibroblasts. Exp Eye Res 2009; 89:256-62.
21. Kamijo S, Nakajima A, Kamata K, et al. Involvement of TWEAK/Fn14 interaction in the synovial inflammation of RA. Rheumatology (Oxford) 2008; 47: 442-50.
22. Subha Rao SD, Joseph MP, Lavi R, et al. Infections related to vascular catheters in a pediatric intensive care unit. Indian Pediatr 2005; 42:667-72.
23. King MM, Rasnake MS, Rodriguez RG, et al. Peripherally inserted central venous catheter-associated thrombosis: retrospective analysis of clinical risk factors in adult patients. South Med J 2006; 99:1073-7.
24. Perper SJ, Browning B, Burkly LC, et al. TWEAK is a novel arthritogenic mediator. J Immunol 2006; 177:2610-20.
25. Leng RX, Pan HF, Qin WZ, et al. TWEAK as a target for therapy in systemic lupus erythematosus. Mol Biol Rep 2011; 38:587-92
26. Ortiz A, Sanz AB, Mun?oz Garc?′a B, et al. Considering TWEAK as a target for therapy in renal and vascular injury. Cytokine Growth Factor Rev 2009; 20:251-8
27. Yepes M. TWEAK and the central nervous system. Mol Neurobiol 2007; 35:255-65
28. Yepes M. TWEAK and FN14 in central nervous system health and disease. Front Biosci 2007; 12:2772-81
29.王茜,潘海峰,李文先,等. IgG型抗dsDNA抗体及其亚型与狼疮肾炎临床和病理关系探讨.中华疾病控制杂志2008; 12: 420-4.
30. Gao HX, Campbell SR, Burkly LC, et al. TNF-like weak inducer of apoptosis (TWEAK) induces inflammatory and proliferative effects in human kidney cells. Cytokine 2009; 46:24-35.
31. Zhao Z, Burkly LC, Campbell S, et al. TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. J Immunol 2007; 179:7949-58.
32. Schwartz N, Rubinstein T, Burkly LC, et al. Urinary TWEAK as a biomarker oflupus nephritis: a multicenter cohort study. Arthritis Res Ther 2009;28:R143
33.陈秋萍,王培光,杜文辉,等.系统性红斑狼疮心脏损害临床研究.中华疾病控制杂志, 2008;12:230-2
34. Asanuma Y, Oeser A, Shintani AK, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. NEngl J Med 2003; 349:2407-15
35.谢遥,程晓曙.肿瘤坏死因子样凋亡微弱诱导剂与动脉粥样硬化.中国动脉硬化杂志2010; 18: 492-4.
36. Blanco-Colio LM, Martín-Ventura JL, Mu?óz-García B, et al. Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27:916-22.
37. Bond M, Fabunmi RP, Baker AH, et al .Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett 1998; 435:29-34.
38. Kim SH, Kang YJ, Kim WJ, et al. TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages. Circ J 2004; 68:396-9.
39. Valesini G, Alessandri C, Celestino D, et al .Anti-endothelial antibodies and neuropsychiatric systemic lupus erythematosus. Ann NY Acad Sci 2006; 1069: 118-28
40. American College of Rheumatology Ad Hoc Committee on Neuropsychiatric Lupus Syndromes. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42:599-608
41. Potrovita I, Zhang W, Burkly L, et al .Tumor necrosis factor-like weak inducer of apoptosis-induced neurodegeneration. J Neurosci 2004; 24:8237-44
42. Yepes M, Brown SA, Moore EG, et al. A soluble Fn14-Fc decoy receptor reduces infarct volume in a murine model of cerebral ischemia. Am J Pathol 2005166:511-20
43. Zhang X, Winkles JA, Gongora MC, et al. TWEAK-Fn14 pathway inhibition protects the integrity of the neurovascular unit during cerebral ischemia. J Cereb Blood Flow Metab 2006; 27:534-44
44. Polavarapu R, Gongora MC, Winkles JA, et al. Tumor necrosis factor-like weak inducer of apoptosis increases the permeability of the neurovascular unit through nuclear factor kappaB pathway activation. J Neurosci 2005; 25:10094-100
45. Desplat-Jego S, Creidy R, Varriale S, et al. Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental autoimmune encephalomyelitis. Clin Immunol 2005; 117:15-23
46. Trysberg E, Blennow K, Zachrisson O, et al. Intrathecal levels of matrix metalloproteinases in systemic lupus erythematosus with central nervous system engagement. Arthritis Res Ther 2004; 6:R551-R556
47. Sanz AB, Justo P, Sanchez-Nin?o MD, et al. The cytokine TWEAK modulates renal tubulointerstitial inflammation. J Am Soc Nephrol 2008; 19:695-703
48. Efthimiou P, Blanco M. Pathogenesis of neuropsychiatric systemic lupus erythematosus and potential biomarkers. Mod Rheumatol 2009 19:457-68
2.曹秀菁,叶冬青,李向培,等.女性系统性红斑狼疮患者血清性激素变化.中华疾病控制杂志, 2004;8:415-7
3. Foster D, Parrish-Novak J, Fox B, et al. Cytokine-receptor pairing: accelerating discovery of cytokine function. Nat Rev Drug Discov 2004; 3:160–70.
4.袁慧,叶冬青. JAK/STAT信号通路与系统性红斑狼疮.中华疾病控制杂志, 2010;14:787-90.
5.陶金辉,李向培,厉小梅,等. IFNγ在系统性红斑狼疮发病中的作用和临床意义.中华疾病控制杂志,2005; 9:278-80.
6. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008; 7:411–25.
7. Nakayama M, Kayagaki N, Yamaguchi N, et al. Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity. J Exp Med 2000; 192:1373- 80.
8. Perper SJ, Browning B, Burkly LC, et al. TWEAK is a novel arthritogenic mediator. J Immunol 2006; 177:2610-20.
9. Kaplan MJ, Lewis EE, Shelden EA, et al. The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells. J Immunol 2002; 169:6020-9.
10. Desplat-Jégo S, Feuillet L, Creidy R, et al. TWEAK is expressed at the cell surface of monocytes during multiple sclerosis. J Leukoc Biol 2009; 85:132-5.
11. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI: a disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum 1992; 35: 630-40.
12.夏江莉,李向培,钱龙,等.系统性红斑狼疮患者血清HMGB1水平检测及临床意义.临床输血与检验, 2009; 11: 242-3.
13. Chicheportiche Y, Bourdon PR, Xu H, et al. TWEAK, a new secreted ligand in the tumor necrosis factor familiy that weakly induces apoptosis. J Biol Chem 1997; 272: 32401-10.
14. Wiley SR, Cassiano L, Lofton T, et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 2001; 15: 837-46.
15. Meighan-Mantha RL, Hsu DK, Guo Y, et al. The mitogen-inducibleFn14 gene encodes a type I transmembrane proteinthat modulates fibroblast adhesion and migration. J Biol Chem 1999; 274: 33166-76.
16. Winkles J A, Tran N L, Brown S A, et al. Role of TWEAK and Fn14 in tumor biology. Front Biosci 2007; 12: 2761-71.
17. Ortiz A, Sanz AB, Mun?oz Garc?′a B, et al. Considering TWEAK as a target for therapy in renal and vascular injury. Cytokine Growth Factor Rev 2009; 20:251-8.
18. Yepes M. TWEAK and the central nervous system. Mol Neurobiol 2007; 35:255- 65.
19. Yepes M. TWEAK and FN14 in central nervous system health and disease. Front Biosci 2007; 12:2772-81.
20. Zhao Z, Burkly LC, Campbell S, et al. TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. J Immunol 2007; 179:7949-58.
21. Schwartz N, Su L, Burkly LC, et al. Urinary TWEAK and the activity of lupus nephritis. J Autoimmun 2006; 27:242-50.
22. Manoharan A, Madaio MP. Biomarkers in lupus nephritis. Rheum Dis Clin North Am 2010; 36:131-43.
23. Chicheportiche Y, Fossati-Jimack L, Moll S, et al. Down-regulated expression of TWEAK mRNA in acute and chronic inflammatory pathologies. Biochem Biophys Res Commun 2000; 279:162-5.
24. Zheng TS, Burkly LC. No end in site: TWEAK/Fn14 activation and autoimmunity associated- end-organ pathologies. J Leukoc Biol 2008; 84:338-47.
25. Leng RX, Pan HF, Qin WZ, et al. TWEAK as a target for therapy in systemic lupus erythematosus. Mol Biol Rep 2011; 38:587-92.
26. ElGendi SS, El-Sherif WT. Anti-C1q antibodies, sCD40L, TWEAK and CD4/CD8 ratio in systemic lupus erythematosus and their relations to disease activity and renal involvement. Egypt J Immunol 2009; 16:135-48.
27. Schwartz N, Rubinstein T, Burkly LC, et al. Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther 2009; 28:R143
1.叶冬青(主编).红斑狼疮.北京:人民卫生出版社, 2006.
2. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008; 7:411-25.
3. Nakayama M, Kayagaki N, Yamaguchi N, et al. Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity. J Exp Med 2000; 192:1373-80.
4. Desplat-Jégo S, Feuillet L, Creidy R, et al. TWEAK is expressed at the cell surface of monocytes during multiple sclerosis. J Leukoc Biol 2009; 85:132-5.
5. Kaplan MJ, Lewis EE, Shelden EA, et al. The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells. J Immunol 2002; 169:6020-9.
6. Chicheportiche Y, Bourdon PR, Xu H, et al. TWEAK, a new secreted ligand in the tumor necrosis factor familiy that weakly induces apoptosis. J Biol Chem 1997; 272: 32 401-10.
7. Lynch CN, Wang YC, Lund J K, et al. TWEA K induces angiogenesis and proliferation of endothelial cells. J Biol Chem 1999; 274: 8455-59.
8. Wiley SR, Cassiano L, Lofton T, et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 2001; 15: 837-46.
9. Meighan-Mantha RL, Hsu DK, Guo Y, et al. The mitogen-inducibleFn14 gene encodes a type I transmembrane proteinthat modulates fibroblast adhesion and migration. J Biol Chem 1999; 274: 33166-76
10. Feng SL, Guo Y, Factor VM, et al. The Fn14 immediateearly response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am J Pathol 2000; 156:1253-61
11. Jakubowski, A. et al. TWEAK induces liver progenitor cell proliferation. J ClinInvest 2005; 115:2330-40
12. Vince JE, Chau D, Callus B, et al. TWEAK-FN14 signaling induces lysosomal degradation of a cIAP1-TRAF2 complex to sensitize tumor cells to TNFalpha. J Cell Biol 2008; 182:171-84.
13. Dai L, Gu L, Ding C, Qiu L, et al. TWEAK promotes ovarian cancer cell metastasis via NF-kappaB pathway activation and VEGF expression. Cancer Lett 2009; 283:159-67
14. Hosokawa Y, Hosokawa I, Ozaki K,et al. Proinflammatory effects of tumour necrosis factor-like weak inducer of apoptosis (TWEAK) on human gingival fibroblasts. Clin Exp Immunol 2006; 146:540-9.
15. Brown SA, Richards CM, Hanscom HN, et al. The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-kappaB activation. Biochem J 2003; 371:395-403.
16. Donohue PJ, Richards CM, Brown SA, et al. TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler Thromb Vasc Biol 2003; 23:594-600.
17. Winkles J A, Tran N L, Brown S A, et al. Role of TWEAK and Fn14 in tumor biology. Front Biosci 2007; 12: 2761-71.
18. Kumar M, Makonchuk DY, Li H, et al. TNF-like weak inducer of apoptosis (TWEAK) activates proinflammatory signaling pathways and gene expression through the activation of TGF-beta-activated kinase 1. J Immunol 2009; 182: 2439-48.
19. Nakayama M, Ishidoh K, Kayagaki N, et al. Multiple pathways of TWEAK-induced cell death. . J Immunol 2002; 168:734-43
20. Ebihara N, Nakayama M, Tokura T, et al. Expression and function of fibroblast growth factor-inducible 14 in human corneal myofibroblasts. Exp Eye Res 2009; 89:256-62.
21. Kamijo S, Nakajima A, Kamata K, et al. Involvement of TWEAK/Fn14 interaction in the synovial inflammation of RA. Rheumatology (Oxford) 2008; 47: 442-50.
22. Subha Rao SD, Joseph MP, Lavi R, et al. Infections related to vascular catheters in a pediatric intensive care unit. Indian Pediatr 2005; 42:667-72.
23. King MM, Rasnake MS, Rodriguez RG, et al. Peripherally inserted central venous catheter-associated thrombosis: retrospective analysis of clinical risk factors in adult patients. South Med J 2006; 99:1073-7.
24. Perper SJ, Browning B, Burkly LC, et al. TWEAK is a novel arthritogenic mediator. J Immunol 2006; 177:2610-20.
25. Leng RX, Pan HF, Qin WZ, et al. TWEAK as a target for therapy in systemic lupus erythematosus. Mol Biol Rep 2011; 38:587-92
26. Ortiz A, Sanz AB, Mun?oz Garc?′a B, et al. Considering TWEAK as a target for therapy in renal and vascular injury. Cytokine Growth Factor Rev 2009; 20:251-8
27. Yepes M. TWEAK and the central nervous system. Mol Neurobiol 2007; 35:255-65
28. Yepes M. TWEAK and FN14 in central nervous system health and disease. Front Biosci 2007; 12:2772-81
29.王茜,潘海峰,李文先,等. IgG型抗dsDNA抗体及其亚型与狼疮肾炎临床和病理关系探讨.中华疾病控制杂志2008; 12: 420-4.
30. Gao HX, Campbell SR, Burkly LC, et al. TNF-like weak inducer of apoptosis (TWEAK) induces inflammatory and proliferative effects in human kidney cells. Cytokine 2009; 46:24-35.
31. Zhao Z, Burkly LC, Campbell S, et al. TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versus-host model of systemic lupus erythematosus. J Immunol 2007; 179:7949-58.
32. Schwartz N, Rubinstein T, Burkly LC, et al. Urinary TWEAK as a biomarker oflupus nephritis: a multicenter cohort study. Arthritis Res Ther 2009;28:R143
33.陈秋萍,王培光,杜文辉,等.系统性红斑狼疮心脏损害临床研究.中华疾病控制杂志, 2008;12:230-2
34. Asanuma Y, Oeser A, Shintani AK, et al. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. NEngl J Med 2003; 349:2407-15
35.谢遥,程晓曙.肿瘤坏死因子样凋亡微弱诱导剂与动脉粥样硬化.中国动脉硬化杂志2010; 18: 492-4.
36. Blanco-Colio LM, Martín-Ventura JL, Mu?óz-García B, et al. Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27:916-22.
37. Bond M, Fabunmi RP, Baker AH, et al .Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Lett 1998; 435:29-34.
38. Kim SH, Kang YJ, Kim WJ, et al. TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages. Circ J 2004; 68:396-9.
39. Valesini G, Alessandri C, Celestino D, et al .Anti-endothelial antibodies and neuropsychiatric systemic lupus erythematosus. Ann NY Acad Sci 2006; 1069: 118-28
40. American College of Rheumatology Ad Hoc Committee on Neuropsychiatric Lupus Syndromes. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42:599-608
41. Potrovita I, Zhang W, Burkly L, et al .Tumor necrosis factor-like weak inducer of apoptosis-induced neurodegeneration. J Neurosci 2004; 24:8237-44
42. Yepes M, Brown SA, Moore EG, et al. A soluble Fn14-Fc decoy receptor reduces infarct volume in a murine model of cerebral ischemia. Am J Pathol 2005166:511-20
43. Zhang X, Winkles JA, Gongora MC, et al. TWEAK-Fn14 pathway inhibition protects the integrity of the neurovascular unit during cerebral ischemia. J Cereb Blood Flow Metab 2006; 27:534-44
44. Polavarapu R, Gongora MC, Winkles JA, et al. Tumor necrosis factor-like weak inducer of apoptosis increases the permeability of the neurovascular unit through nuclear factor kappaB pathway activation. J Neurosci 2005; 25:10094-100
45. Desplat-Jego S, Creidy R, Varriale S, et al. Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental autoimmune encephalomyelitis. Clin Immunol 2005; 117:15-23
46. Trysberg E, Blennow K, Zachrisson O, et al. Intrathecal levels of matrix metalloproteinases in systemic lupus erythematosus with central nervous system engagement. Arthritis Res Ther 2004; 6:R551-R556
47. Sanz AB, Justo P, Sanchez-Nin?o MD, et al. The cytokine TWEAK modulates renal tubulointerstitial inflammation. J Am Soc Nephrol 2008; 19:695-703
48. Efthimiou P, Blanco M. Pathogenesis of neuropsychiatric systemic lupus erythematosus and potential biomarkers. Mod Rheumatol 2009 19:457-68